Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
350
Frequently Asked Questions
What is Market Cap of Halozyme Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Halozyme Therapeutics Inc. market cap is $8.59B.
What is the 52-week high for Halozyme Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Halozyme Therapeutics Inc. 52 week high is $75.46 as of September 06, 2025.
What is the 52-week low for Halozyme Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Halozyme Therapeutics Inc. 52 week low is $42.01 as of September 06, 2025.
What is Halozyme Therapeutics Inc. stock price today?
Halozyme Therapeutics Inc. stock price today is $74.93.
What was Halozyme Therapeutics Inc. stock price yesterday?
Halozyme Therapeutics Inc. stock price yesterday was $73.40.
What is the PE ratio of Halozyme Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Halozyme Therapeutics Inc.’s P/E ratio is 16.77.
What is the Price-to-Book ratio of Halozyme Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Halozyme Therapeutics Inc. P/B ratio is 25.9457.
What is the 50-day moving average of Halozyme Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Halozyme Therapeutics Inc. 50-day moving average is $61.90.
How many employess does Halozyme Therapeutics Inc. has?